keyword
https://read.qxmd.com/read/38505997/glucagon-like-peptide-1-receptor-agonists-modestly-reduced-blood-pressure-among-patients-with-and-without-diabetes-mellitus-a-meta-analysis-and-meta-regression
#1
JOURNAL ARTICLE
Frederick Berro Rivera, Grace Nooriza O Lumbang, Danielle Rose Magno Gaid, Linnaeus Louisse A Cruz, John Vincent Magalong, Nathan Ross B Bantayan, Kyla M Lara-Breitinger, Martha Gulati, George Bakris
AIM: The cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycaemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP-lowering effects of GLP1-RAs. METHODS: A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with a mean difference (MD) in mmHg and 95% confidence intervals (CIs)...
March 20, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38494045/intestinal-alterations-and-mild-glucose-homeostasis-impairments-in-the-offspring-born-to-overweight-rats
#2
JOURNAL ARTICLE
Florencia Heinecke, Daiana Fornes, Evangelina Capobianco, Jeremías Pablo Flores Quiroga, Marina Labiano, Alicia Graciela Faletti, Jawerbaum, Verónica White
The gut plays a crucial role in metabolism by regulating the passage of nutrients, water and microbial-derived substances to the portal circulation. Additionally, it produces incretins, such as glucose-insulinotropic releasing peptide (GIP) and glucagon-like derived peptide 1 (GLP1, encoded by gcg gene) in response to nutrient uptake. We aimed to investigate whether offspring from overweight rats develop anomalies in the barrier function and incretin transcription. We observed pro-inflammatory related changes along with a reduction in Claudin-3 levels resulting in increased gut-permeability in fetuses and offspring from overweight rats...
March 15, 2024: Molecular and Cellular Endocrinology
https://read.qxmd.com/read/38474208/semaglutide-improves-liver-steatosis-and-de-novo-lipogenesis-markers-in-obese-and-type-2-diabetic-mice-with-metabolic-dysfunction-associated-steatotic-liver-disease
#3
JOURNAL ARTICLE
Manuel Soto-Catalán, Lucas Opazo-Ríos, Hernán Quiceno, Iolanda Lázaro, Juan Antonio Moreno, Carmen Gómez-Guerrero, Jesús Egido, Sebastian Mas-Fontao
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a prevalent clinical condition associated with elevated morbidity and mortality rates. Patients with MASLD treated with semaglutide, a glucagon-like peptide-1 receptor agonist, demonstrate improvement in terms of liver damage. However, the mechanisms underlaying this beneficial effect are not yet fully elucidated. We investigated the efficacy of semaglutide in halting MASLD progression using a genetic mouse model of diabesity. Leptin-receptor-deficient mice with obesity and diabetes (BKS db/db) were either untreated or administered with semaglutide for 11 weeks...
March 4, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473732/potential-mechanisms-of-the-protective-effects-of-the-cardiometabolic-drugs-type-2-sodium-glucose-transporter-inhibitors-and-glucagon-like-peptide-1-receptor-agonists-in-heart-failure
#4
REVIEW
Giovanna Gallo, Massimo Volpe
Different multifactorial pathophysiological processes are involved in the development of heart failure (HF), including neurohormonal dysfunction, the hypertrophy of cardiomyocytes, interstitial fibrosis, microvascular endothelial inflammation, pro-thrombotic states, oxidative stress, decreased nitric oxide (NO) bioavailability, energetic dysfunction, epicardial coronary artery lesions, coronary microvascular rarefaction and, finally, cardiac remodeling. While different pharmacological strategies have shown significant cardiovascular benefits in HF with reduced ejection fraction (HFrEF), there is a residual unmet need to fill the gap in terms of knowledge of mechanisms and efficacy in the outcomes of neurohormonal agents in HF with preserved ejection fraction (HFpEF)...
February 20, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38471571/the-pathophysiological-associations-between-obesity-nafld-and-atherosclerotic-cardiovascular-diseases
#5
JOURNAL ARTICLE
Meng Li, Man Cui, Guoxia Li, Yueqiu Liu, Yunsheng Xu, Seyed Parsa Eftekhar, Moein Ala
Obesity, non-alcoholic fatty liver disease (NAFLD), and atherosclerotic cardiovascular diseases are common and growing public health concerns. Previous epidemiological studies unfolded the robust correlation between obesity, NAFLD, and atherosclerotic cardiovascular diseases. Obesity is a well-known risk factor for NAFLD, and both of them can markedly increase the odds of atherosclerotic cardiovascular diseases. On the other hand, significant weight loss achieved by lifestyle modification, bariatric surgery, or medications, such as semaglutide, can concomitantly improve NAFLD and atherosclerotic cardiovascular diseases...
March 12, 2024: Hormone and Metabolic Research
https://read.qxmd.com/read/38441504/young-onset-type2-diabetes-when-gluconeogenesis-is-overfueled-and-out-of-control
#6
EDITORIAL
Francois Alhenc-Gelas, Michel Marre
No abstract text is available yet for this article.
March 5, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38436920/adjuvant-glucose-like-peptide-1-receptor-agonist-therapy-for-suboptimal-weight-loss-after-bariatric-surgery-a-systematic-review
#7
REVIEW
Alexandre Dréant, Claire Blanchard, David Jacobi
Addressing suboptimal weight loss post-bariatric surgery poses a challenge. While glucagon-like peptide 1 receptor agonists (GLP1-RA) show promise in managing obesity, their role as an adjuvant treatment after bariatric surgery remains uncertain. We conducted a systematic literature review focused on the efficacy and safety of GLP1-RA in bariatric surgery patients with insufficient weight loss or distant weight regain. Our literature search identified 1167 articles, with 10 (involving 594 patients) meeting inclusion/exclusion criteria for detailed review...
March 4, 2024: Obesity Surgery
https://read.qxmd.com/read/38430320/semaglutide-and-tirzepatide-for-the-management-of-weight-recurrence-after-sleeve-gastrectomy-a-retrospective-cohort-study
#8
JOURNAL ARTICLE
Mohammad Jamal, Mohsen Alhashemi, Carol Dsouza, Sara Al-Hassani, Wafa Qasem, Sulaiman Almazeedi, Salman Al-Sabah
BACKGROUND: Metabolic and bariatric surgery (MBS) is the most effective treatment for obesity and improvement of obesity-associated comorbidities. However, a proportion of these patients may suffer from weight recurrence and recurrence of obesity-associated comorbidities. METHOD: A retrospective cohort study of patients who underwent SG between January 2008 and August 2022 and sought treatment for weight recurrence with semaglutide or tirzepetide from January 2022 onwards...
March 2, 2024: Obesity Surgery
https://read.qxmd.com/read/38417475/tirzepatide-a-novel-cardiovascular-protective-agent-in-type-2-diabetes-mellitus-and-obesity
#9
REVIEW
Muhammad Bilal Sardar, Zain Ali Nadeem, Muhammad Babar
Cardiovascular disease (CVD) remains a major global health concern, and obesity and diabetes mellitus have been found to be important risk factors. Tirzepatide a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP1) receptor agonist has been shown to have cardioprotective effects. Noteworthy benefits of Tirzepatide include decreased cardiovascular risk factors in people with Type 2 diabetes mellitus (T2DM). In the SURPASS-4 trial, tirzepatide significant decreased blood pressure, body weight, and HbA1c...
February 28, 2024: Current Problems in Cardiology
https://read.qxmd.com/read/38408098/comparative-effectiveness-of-glucagon-like-peptide-1-receptor-agonists-on-body-composition-and-anthropometric-indices-a-protocol-for-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials
#10
COMPARATIVE STUDY
Nuttaya Wachiraphansakul, Thanawat Vongchaiudomchoke, Worapaka Manosroi, Surapon Nochaiwong
BACKGROUND: To date, no studies have addressed the comparative efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) therapy on body composition and anthropometric indices among adult overweight or obese patients with or without type 2 diabetes. To provide evidence-based recommendations, we will conduct a traditional pairwise and network meta-analysis of all available randomized clinical trials that evaluated the effects of GLP1-RAs interventions for adult overweight or obese patients with or without type 2 diabetes...
2024: PloS One
https://read.qxmd.com/read/38407195/assessment-and-management-of-patients-with-obesity-and-hypertension-in-european-society-of-hypertension-excellence-centres-a-survey-from-the-esh-working-group-on-diabetes-and-metabolic-risk-factors
#11
JOURNAL ARTICLE
Christina Antza, Guido Grassi, Thomas Weber, Alexandre Persu, Jens Jordan, Peter M Nilsson, Josep Redon, Stella Stabouli, Reinhold Kreutz, Vasilios Kotsis
BACKGROUND: Healthcare providers are faced with an increasing number of patients with obesity and arterial hypertension. Preventing obesity-associated hypertension and appropriately managing patients with established disease are both important. Hence, the aim of our study was to evaluate the clinical care of patients with obesity and hypertension among ESH Excellence Centres (ECs). METHODS: We conducted a cross-sectional, international 30-item survey through e-mails...
December 2024: Blood Pressure
https://read.qxmd.com/read/38402868/semaglutide-a-long-acting-glp-1-analogue-for-the-management-of-early-onset-obesity-due-to-mc4r-defect-a-case-report
#12
Pon Ramya Gokul, Louise Apperley, Jennifer Parkinson, Kate Clark, Kim Lund, Megan Owens, Senthil Senniappan
INTRODUCTION: Childhood obesity is a global concern and has both nutritional and genetic causative factors. One of the most common monogenic causes of obesity is heterozygous mutations in the Melanocortin 4 receptor (MC4R), which are found in 5.7% to 8.6% of individuals with early-onset obesity. We report, the effect of Semaglutide, a long-acting Glucagon like peptide (GLP1) analogue, in the treatment of severe obesity in an adolescent boy with a heterozygous mutation in MC4R. CASE PRESENTATION: A 13-year-old boy with a history of excessive weight gain since infancy was referred to the specialised weight management team...
February 23, 2024: Hormone Research in Pædiatrics
https://read.qxmd.com/read/38369509/role-of-gastric-bypass-surgery-in-control-of-blood-sugar-in-obese-uncontrolled-type-2-diabetic-patients
#13
JOURNAL ARTICLE
Hala Khalf Allah El-Shreef, Osama Yaseen Mostafa Taha, Heba Ahmed Abd El Hafeez, Amal Ibrahim Abd El-Rheem Abo Shoka
BACKGROUND AND GOAL: The pandemic of the twenty-first century is diabetes. Both type 2 diabetes mellitus and obesity pose severe problems for public health. Despite significant improvements in diagnosing and managing both conditions, diabetes mellitus remains poorly controlled, and diabetic complications are more common than ever. Internists have discovered over the past 20 years that obese people with type 2 diabetes who have gastric bypass surgery to shed weight have improved glycemic control...
February 19, 2024: Diabetology & Metabolic Syndrome
https://read.qxmd.com/read/38355887/anti-obesity-pharmacological-agents-for-polycystic-ovary-syndrome-a-systematic-review-and-meta-analysis-to-inform-the-2023-international-evidence-based-guideline
#14
REVIEW
Alyse Goldberg, Sandro Graca, Jing Liu, Vibhuti Rao, Selma Feldman Witchel, Alexia Pena, Rong Li, Aya Mousa, Chau Thien Tay, Loyal Pattuwage, Helena Teede, Bulent O Yildiz, Carolyn Ee
This systematic review and meta-analysis evaluated the efficacy of anti-obesity agents for hormonal, reproductive, metabolic, and psychological outcomes in polycystic ovary syndrome (PCOS) to inform the 2023 update of the International Evidence-based Guideline on PCOS. We searched Medline, EMBASE, PsycInfo, and CINAHL until July 2022 with a 10-year limit to focus on newer agents. Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included. On descriptive analyses, most agents improved anthropometric outcomes; liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes...
February 14, 2024: Obesity Reviews
https://read.qxmd.com/read/38339799/evaluating-appetite-satiety-hormones-and-eating-behaviours-as-predictors-of-weight-loss-maintenance-with-glp-1ra-therapy-in-adolescents-with-severe-obesity
#15
JOURNAL ARTICLE
Megan O Bensignor, Aaron S Kelly, Alicia Kunin-Batson, Claudia K Fox, Rebecca Freese, Justin Clark, Kyle D Rudser, Eric M Bomberg, Justin Ryder, Amy C Gross
INTRODUCTION: Whilst glucagon-like peptide-1 receptor agonists (GLP1-RAs) are effective for treating adolescent obesity, weight loss maintenance (WLM; preventing weight regain) remains a challenge. Our goal was to investigate appetite/satiety hormones and eating behaviours that may predict WLM with exenatide (a GLP1-RA) versus placebo in adolescents with severe obesity. METHODS: Adolescents who had ≥5% body mass index (BMI) reduction with meal replacement therapy were randomized to 52 weeks of once-weekly exenatide extended release or placebo...
February 9, 2024: Pediatric Obesity
https://read.qxmd.com/read/38299776/how-to-assess-kidney-outcomes-in-obese-people-with-substantial-weight-loss-the-case-of-glp1-and-dual-receptor-agonists
#16
JOURNAL ARTICLE
Amy E Rothberg, William H Herman
No abstract text is available yet for this article.
January 31, 2024: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/38228492/net-prices-of-new-antiobesity-medications
#17
JOURNAL ARTICLE
Inmaculada Hernandez, Sean D Sullivan
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP1s) are effective antiobesity drugs and the subject of intense debate around insurance coverage due to the large prevalence of obesity and overweight. The estimation of the budget impact associated with GLP1 insurance coverage requires estimates of GLP1 prices that account for manufacturer discounts. The authors applied a peer-reviewed method to estimate the net prices of GLP1s after manufacturer discounts. METHODS: The authors estimated manufacturer discounts for each product as the difference between the gross sales estimated at list price and manufacturer-reported revenue...
January 16, 2024: Obesity
https://read.qxmd.com/read/38201269/glp1-receptor-agonists-effects-beyond-obesity-and-diabetes
#18
REVIEW
Sydney S Wilbon, Mikhail G Kolonin
Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability of which is continuously improving, enable weight loss and control blood glucose with minimal unwanted side effects. Since adopting GLP1RA for treating metabolic diseases, animal and clinical studies have revealed their beneficial effects on several other pathologies, including cardiovascular diseases, neurodegeneration, kidney disease, and cancer...
December 28, 2023: Cells
https://read.qxmd.com/read/38192938/rhabdomyolysis-associated-with-semaglutide-therapy-a-case-report
#19
Sabrina A Billings, Heidi M Felix, Cara C Prier, Mary S Hedges
This report describes the case of a 47-year-old woman with myalgias, weakness, and elevated creatine kinase associated with semaglutide therapy prescribed for weight loss. Her symptoms and laboratory markers were consistent with rhabdomyolysis and resolved after discontinuation of semaglutide. Upon rechallenge at a lower dose, symptoms recurred, and urinalysis was consistent with myoglobinuria. Symptoms again rapidly resolved upon discontinuation of the medication. It is imperative for physicians to recognize semaglutide as a possible cause of myalgias and rhabdomyolysis in clinically suspected patients...
December 2023: Curēus
https://read.qxmd.com/read/38187405/chronic-glp1-therapy-reduces-postprandial-il6-in-obese-humans-with-prediabetes
#20
JOURNAL ARTICLE
Vala Hamidi, Hongyu Wang, Vi Pham, Karla Bermudez Saint Andre, Heinrich Taegtmeyer, Absalon D Gutierrez
Single-dose glucagon-like peptide 1 (GLP1) therapy increases postprandial plasma IL6 levels in prediabetic, obese humans. GLP1-IL6 interactions underly multiple antidiabetic effects, but these may differ after acute versus chronic therapy. This study examines postprandial effects of GLP1 after chronic therapy. Seven humans (six Black) with prediabetes and obesity completed 6 weeks of exenatide extended release therapy. Then subjects returned for pre- and post-meal measurements of plasma IL6, GLP1, glucagon, and related inflammatory markers...
March 2024: Cardiovascular endocrinology & metabolism
keyword
keyword
54958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.